Jul. 8 at 11:23 PM
$CMPS ✅👍✅👍✅👍✅
$70. Says HC Weinwright 👍
Analysts currently have a consensus "Strong Buy" to "Moderate Buy" rating on COMPASS Pathways, with an average 12-month price target of approximately
$22.88 to
$24.15. Projections from Wall Street firms range from a low of
$8.00 to a high street target of
$70.00. [1, 2, 3]
Following positive Phase 3 and durability data regarding its COMP360 psilocybin therapy for treatment-resistant depression, several major firms updated their ratings and price targets for COMPASS Pathways in July 2026: [1, 2, 3]
* BTIG: Maintained a "Buy" rating and raised their price target to
$25.00 (from
$14.00).
* Stifel: Maintained a "Buy" rating and raised their price target to
$21.00 (from
$14.00).
* Oppenheimer: Maintained an "Outperform" rating with a price target of
$20.00.
* ✅HC Wainwright : Reiterated BUY rating and raised Maintains a
$70 price target
* ( Source Schwab; Benzinga News Wire )
Sure beats
$LLY and
$PFE
